Medline Inc. faced a key test of investor demand Friday as some of its largest shareholders priced an upsized secondary offering of 72.6 million shares at $37 apiece, raising approximately $2.68 billion. The medical-supply company itself will not receive any proceeds from the sale, which was increased from an initial 60 million-share target.
Shares of the Northfield, Illinois-based company traded near $37.08 late Friday, holding above the $29 initial public offering price from December but well below the 52-week high of $50.88. The stock's performance around the offering price provides a fresh read on market appetite for one of last year's largest U.S. listings.
Major Backers Cash Out
The selling shareholders include affiliates of private equity firms Blackstone and Hellman & Friedman, as well as a unit of the Abu Dhabi Investment Authority, according to Medline's filings. Underwriters, led by Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan, have a 30-day option to purchase an additional 10.9 million shares.
The timing of the secondary offering is significant as Medline went public only in December 2025, with its IPO closing at 248.4 million shares sold at $29 each after underwriters fully exercised their option. The stock opened at $35 on its first trading day and closed at $41, according to Reuters.
Business Fundamentals and Tariff Headwinds
Medline competes in the medical-surgical supply and distribution sector, going head-to-head with healthcare logistics giants such as McKesson and Cardinal Health. Unlike high-growth biotech listings, Medline offers a more established business model focused on high-volume hospital products, private-label supplies, and supply-chain services.
The company reported first-quarter net sales of $7.4 billion, up 10.7% year-over-year. However, net income fell 25.8% to $239 million, weighed down by higher cost of goods sold, tariffs, operating expenses, and an IPO-related employee bonus. Adjusted EBITDA dropped 10.6% to $776 million.
Tariffs remain a significant overhang. Chief Financial Officer Mike Drazin disclosed that the company experienced about $120 million in tariff impacts during the first quarter, with $85 million directly tied to tariff changes. CEO Jim Boyle stated the company would first attempt to absorb or offset pressure internally before passing costs to customers.
Market Implications
The secondary offering could cap near-term gains if investors interpret the sale as a signal that early owners seek liquidity while margins are under pressure. The downside scenario includes further tariff or freight cost increases, slower hospital spending, or additional insider selling, which could push Medline's stock to trade more like a levered distributor than a prized IPO scarcity play.
Nevertheless, the stock has maintained a premium to its IPO price. Jeff Zell, senior research analyst at IPO Boutique, noted in December that Medline is "profitable, cash-generative, and well understood," a profile that differs from typical growth IPOs. Friday's block sale now tests whether that argument still holds at $37.
With U.S. markets heading into a long Memorial Day weekend, the Medline block has been priced but not yet closed, leaving investors to digest the implications of the offering and the company's outlook for the remainder of 2026.
